Apoptotic pathways in tumor progression and therapy

被引:0
作者
Melet, Armelle [1 ]
Song, Keli [1 ]
Bucur, Octavian [1 ]
Jagani, Zainab [1 ]
Grassian, Alexandra R. [1 ]
Khosravi-Far, Roya [1 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA
来源
PROGRAMMED CELL DEATH IN CANCER PROGRESSION AND THERAPY | 2008年 / 615卷
关键词
apoptosis; cancer; therapy; inhibitors; signal transduction; oncogene; intrinsic; extrinsic;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Apoptosis is a cell suicide program that plays a critical role in development and tissue homeostasis. The ability of cancer cells to evade this programmed cell death (PCD) is a major characteristic that enables their uncontrolled growth. The efficiency of chemotherapy in killing such cells depends on the successful induction of apoptosis, since defects in apoptosis signaling are a major cause of drug resistance. Over the past decades, much progress has been made in our understanding of apoptotic signaling pathways and their dysregulation in cancer progression and therapy. These advances have provided new molecular targets for proapoptotic cancer therapies that have recently been used in drug development. While most of those therapies are still at the preclinical stage, some of them have shown much promise in the clinic. Here, we review our current knowledge of apoptosis regulation in cancer progression and therapy, as well as the new molecular targeted molecules that are being developed to reinstate cancer cell death.
引用
收藏
页码:47 / 79
页数:33
相关论文
共 291 条
[1]   Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].
Aas, T ;
Borresen, AL ;
Geisler, S ;
SmithSorensen, B ;
Johnsen, H ;
Varhaug, JE ;
Akslen, LA ;
Lonning, PE .
NATURE MEDICINE, 1996, 2 (07) :811-814
[2]  
Abe K, 2000, ANN NY ACAD SCI, V926, P52
[3]   The proteasome: structure, function, and role in the cell [J].
Adams, J .
CANCER TREATMENT REVIEWS, 2003, 29 :3-9
[4]   Development of the proteasome inhihitor Veleade™ (Bortezomib) [J].
Adams, J ;
Kauffman, M .
CANCER INVESTIGATION, 2004, 22 (02) :304-311
[5]   THE C-MYC ONCOGENE DRIVEN BY IMMUNOGLOBULIN ENHANCERS INDUCES LYMPHOID MALIGNANCY IN TRANSGENIC MICE [J].
ADAMS, JM ;
HARRIS, AW ;
PINKERT, CA ;
CORCORAN, LM ;
ALEXANDER, WS ;
CORY, S ;
PALMITER, RD ;
BRINSTER, RL .
NATURE, 1985, 318 (6046) :533-538
[6]   Apoptosomes: engines for caspase activation [J].
Adams, JM ;
Cory, S .
CURRENT OPINION IN CELL BIOLOGY, 2002, 14 (06) :715-720
[7]   Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML):: evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides [J].
Aichberger, KJ ;
Mayerhofer, M ;
Krauth, MT ;
Skvara, H ;
Florian, S ;
Sonneck, K ;
Akgul, C ;
Derdak, S ;
Pickl, WF ;
Wacheck, V ;
Selzer, E ;
Monia, BP ;
Moriggl, R ;
Valent, P ;
Sillaber, C .
BLOOD, 2005, 105 (08) :3303-3311
[8]   Molecular ordering of the initial signaling events of CD95 [J].
Algeciras-Schimnich, A ;
Shen, L ;
Barnhart, BC ;
Murmann, AE ;
Burkhardt, JK ;
Peter, ME .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (01) :207-220
[9]   ONCOGENE AMPLIFICATION IN TUMOR-CELLS [J].
ALITALO, K ;
SCHWAB, M .
ADVANCES IN CANCER RESEARCH, 1986, 47 :235-281
[10]   Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy [J].
Almasan, A ;
Ashkenazi, A .
CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (3-4) :337-348